Overview
- The company will enlarge its Frederick biologics facility and construct a new clinical manufacturing site in Gaithersburg to support development and trial supply.
- AstraZeneca says the Frederick upgrade will nearly double commercial capacity and introduce production across its rare disease portfolio for the first time at the site.
- Both Maryland facilities are planned to be operational in 2029, aligning with the company’s broader U.S. buildout timeline.
- The projects will support about 2,600 jobs, including 300 highly skilled positions, with 200 high‑skill roles and 900 construction jobs tied to Frederick and about 100 new jobs, 400 retained roles, and roughly 1,000 construction jobs in Gaithersburg.
- Maryland will provide a 10% investment match, and the governor called it the state’s largest private investment in at least a decade, following earlier U.S. commitments in Rockville, Virginia, and Coppell, Texas.